Adherence to Ivacaftor is suboptimal

Abbott, Janice orcid iconORCID: 0000-0001-9851-1236 and Bilton, Diana (2015) Adherence to Ivacaftor is suboptimal. Journal of Cystic Fibrosis, 14 (5). pp. 547-548. ISSN 1569-1993

[thumbnail of Author Accepted Manuscript]
PDF (Author Accepted Manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.


Official URL:


Ivacaftor, the first cystic fibrosis (CF) transmembrane conductance regulator (CFTR) potentiator provides a remarkable example of personalised medicine that has the capacity to transform lives and patient care. For those with a CFTR-G551D mutation, two phase three trials (adult and paediatric age 6+ years) and a follow-up open label trial have demonstrated remarkable and sustained improvements in CFTR function, FEV1 (approximately 10% points) and a reduction in pulmonary exacerbations with Ivacaftor 150 mg every 12 h [1–3].

Repository Staff Only: item control page